Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
Want to see HK:2252 full AI Analyst Report?
2252 Stock Chart & Stats
HK$34.14
-HK$0.03(-0.33%)
At close: 4:00 PM EST
HK$34.14
-HK$0.03(-0.33%)
Day’s Range― - ―
52-Week RangeHK$14.58 - HK$35.34
Previous CloseN/A
Volume4.35M
Average Volume (3M)5.91M
Market Cap
HK$30.06B
Enterprise ValueHK$26.22B
Total Cash (Recent Filing)HK$640.42M
Total Debt (Recent Filing)HK$426.37M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Sep 02, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)54.27
Price to Sales (P/S)41.54
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$40.00Price Target Upside17.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$1.09B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Acceleration (2025)A sustained jump to ~61% revenue growth in 2025 signals improving commercial traction and market adoption of the company’s surgical robotic platforms. Over 2–6 months this supports scale benefits: higher unit volumes can amortize fixed R&D and sales costs, enabling a credible pathway to sustained margin improvement if growth persists.
Positive Gross Margins On Product SalesA ~29% gross margin indicates the company has fundamentally positive unit economics for its robotics systems and consumables. That structural margin gives the business a foundation to attain operating profitability as scale improves and SG&A leverage is realized, making long-run profitability achievable if revenue growth continues.
Meaningful Improvement In LeverageA sharp reduction in debt-to-equity from ~2.5 to ~1.0 materially lowers solvency and interest burden risks. That durable improvement increases financial flexibility to fund product rollouts and clinical adoption, reduces refinancing risk over the medium term, and strengthens the balance sheet versus prior leverage-driven constraints.
Bears Say
Persistent Negative Operating And Free Cash FlowRepeated negative operating and free cash flow means the company remains reliant on external financing or asset sales to fund operations. Over months this constrains capital allocation, risks dilution or higher-cost debt, and limits the firm’s ability to self-fund commercialization and after-sales support critical to medical device adoption.
Large Net Loss And Negative Net MarginA net margin near -45% reflects material operating losses that erode retained capital and make sustainable profitability a multi-step process. Persistent deep losses reduce runway, pressure pricing/expense trade-offs, and mean management must deliver consistent margin improvement alongside growth to avoid chronic capital raises.
Deeply Negative ROE And Equity ErosionROE of about -59% signals that the company is destroying shareholder value and that equity has been eroded. Structurally this hampers the ability to raise equity on attractive terms, increases reliance on debt or dilutive financings, and constrains long-term investment capacity unless profitability reverses materially.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$14.58 and its highest was HK$35.34 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$30.06B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 117 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.161 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.161.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate is -0.01.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,030,720,600 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of -HK$0.161 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.136%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
-52.30%
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
2252 Stock 12 Month Forecast
Average Price Target
HK$40.00
▲(17.16% Upside)
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---